Here is a summary of the current health briefs.
Biden receives COVID-19 booster shot as additional doses roll out
US President Joe Biden rolled up his shirt sleeve and received a COVID-19 vaccine booster on Monday, hoping to provide a powerful example for Americans of the need to get the extra blow even as millions people do without their first. “Boosters are important, but the most important thing we need to do is get more people vaccinated,” he said, noting that about 23% of people in the United States have not received any. vaccine.
US administers 390.7 million doses of COVID-19 vaccine – CDC
The United States administered 390,664,923 doses of COVID-19 vaccines nationwide as of Monday morning and distributed 471,818,715 doses, the United States Centers for Disease Control and Prevention said. Those numbers are up from the 390,114,328 doses of vaccine that the CDC said took to arms on Sunday.
Japan to end COVID-19 state of emergency this month
Japan will lift the coronavirus state of emergency in all regions on Thursday as the number of new cases declines and pressure on the medical system eases, Economy Minister Yasutoshi Nishimura said. The plan, approved by a government advisory group, brings Japan as a whole out of a state of emergency for the first time in nearly six months. Prime Minister Yoshihide Suga will hold a press conference at 7 p.m. (1000 GMT) to announce the decision after the plan is formalized by a government task force.
Sydney unvaccinated warned of social isolation as COVID-19 lockdown ends
Sydney residents who are not vaccinated against COVID-19 risk being excluded from various social activities even when released from stay-at-home orders in December, the New State Prime Minister warned on Tuesday. -South Wales, Gladys Berejiklian. As part of a roadmap to get out of lockdown in Australia’s largest city, unvaccinated people are already subject to delays in freedoms that will be gradually granted to residents vaccinated between October 11 and December 1 .
India reports smallest increase in COVID-19 deaths since mid-March
India reported 179 deaths from COVID-19 on Tuesday, the smallest increase since mid-March, bringing the total to 447,373. Infections increased by 18,795, the smallest increase since early March, bringing the total to about 33.7 million, according to data from the Department of Health.
Eisai and Biogen Launch Fast-Track US Approval for New Alzheimer’s Disease Drug
Japanese drug maker Eisai Co on Monday began the application process for its investigational drug for the treatment of early-onset Alzheimer’s disease using a fast-track approval path, the same path that helped Eisai’s development partner , Biogen Inc, to get US approval for its drug in June. The drug Biogen / Eisai Aduhelm was the first Alzheimer’s disease treatment to gain approval in nearly 20 years, but the Food and Drug Administration’s (FDA) controversial use of the fast-track approval process – which clears drugs for serious conditions without strong evidence of patient benefit – has come under heavy fire.
New York hospitals lay off and suspend staff who refuse COVID vaccine
New York hospitals began firing or suspending healthcare workers on Monday for defying a state order to obtain the COVID-19 vaccine, and the resulting staff shortages prompted some hospitals postpone elective surgeries or reduce services. New York City Mayor Bill de Blasio told a news conference that city hospitals were not yet seeing a major impact from the mandate, adding that he was concerned about other parts of the city. ‘State with lower vaccination rates.
EU examines data on Moderna’s COVID-19 recall
The European Union (EU) medicines regulator said on Monday it was evaluating whether a booster dose of Moderna’s COVID-19 vaccine could be given at least six months after the second injection of the two-dose course in people over 12 years old. The review by the European Medicines Agency (EMA) comes after its statement last week that it aims to decide in early October whether or not to approve a booster for the Pfizer-BioNTech vaccine, nearly a month after it started. of the evaluation process.
The protein found on infected cells protects the virus from the immune system; remdesivir helps prevent hospitalization
The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the results and that has not yet been peer-certified. Cells infected with the virus protected by proteins from the immune system
Pfizer begins study of mRNA influenza vaccine
Pfizer Inc said Monday it administered the first patient in a trial testing an influenza vaccine based on messenger RNA, the same technology used in COVID-19 injections made by the U.S. drug maker and BioNTech. The early-stage trial, conducted in the United States, will test the vaccine in healthy adults aged 65 to 85.
(This story was not edited by Devdiscourse staff and is auto-generated from a syndicated feed.)